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Abstract 
Mucosal immunization with the conserved Shigella protein IpaD formulated with the two-component adjuvant IC31® 
provided protection in the murine lung model. Neither the recombinant IpaD alone nor IC31® with an irrelevant 
protein antigen was effective. IpaD-specific serum IgG and IgA levels obtained by IC31®-adjuvantation were 
comparable to those induced by known mucosal adjuvants.  
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1. Introduction 
Bacillary dysentery caused by Shigella spp. is a significant cause of mortality and morbidity in 
developing countries [1-3]. Vaccine development is hindered by the numerous serotypes of Shigella spp., 
which differ in the chemical composition of LPS O-antigens. Most of the experimental vaccines are 
multivalent in order to provide a broad coverage [4,5]. An alternative strategy for novel vaccines would 
be to target highly conserved surface proteins involved in pathogenesis. Previous studies demonstrated 
that the invasion plasmid antigens (Ipa-s) comprising the type-three secretion system (T3SS) required for 
invasiveness [6] are naturally immunogenic [7,8].  Intercell AG also confirmed the immunogenicity of the 
Shigella Ipa complex proteins by screening genomic bacterial surface display libraries [9,10] expressing 
Shigella peptides with human serum antibodies obtained from adults living in endemic regions  (int. 
patent appl.: WO/2005/103073; http://www.wipo.int/pctdb/en/wo.jsp?wo=2005103073). However, no 
single protein component of the invasion complex has been shown to provide protection so far [11]. 
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Moreover, the current notion is that recovery from shigellosis does not provide immunity against 
infections with different serotypes. It implies that natural immune response to the single protein 
components is not protective, or requires multiple exposures. An alternative explanation is that most Ipa-s 
are expressed exclusively upon contact with the target cells to be invaded [12-14] and/or they are masked 
by LPS. Nevertheless, it was shown that the length of LPS is optimized by glycosylation to allow access 
of the T3SS apparatus to the target cell [15]. The IpaD protein is located at the tip of T3SS apparatus [16] 
and forms a plug, which is involved in the fine tuned regulation of the translocon complex [12,17]. As 
such, IpaD is at least partially exposed at the tip of the T3SS [18] and hence serves as an attractive target 
for antibody mediated vaccine strategies. Antibodies against corresponding T3SS tip proteins of other 
Gram-negative pathogens were already shown to elicit protection [19-21].  Here, we have assessed the 
potential of using IpaD as a mucosal vaccine against shigellosis in a murine model. 
 
2. Materials and Methods 
2.1. Antigen formulations 
The genes encoding IpaD and OspA (an irrelevant antigen) were amplified from genomic DNA of 
Shigella flexneri 2a strain 2457T and Borrelia burgdorferi strain N40, respectively, using primers shown 
in Table 1.  
Table 1. Oligonucleotides used in this study  
Designation Sequence R.E. Function 
210-5981 a ATATATCCATGGGCAATATAACAACTCTGACTAATAGTATTTC NcoI 
cloning of IpaD 
210-5982 a ATATATCTCGAGGAAATGGAGAAAAAGTTTATCTG XhoI 
210-7233 a ATATATCCATGGCTTGTAAGCAAAATGTTAGCAGCCTTGAC NcoI 
cloning of OspA 
210-7234 a ATATATCTCGAGTTTTAAAGCGTTTTTAATTTCATCAAGTTTTG XhoI 
401-7965 b AAATATTCGTGGTTATGCGCCTCAGATTACTGGTATTGCAGTG
TAGGCTGGAGCTGCTTC 
- 
generation of cassette 
used for labelling of the 
invasion plasmid 401-7966 
b AACATCCAATATTCCTCGTACAGAACTACTCAAGTCCTGACAT
ATGAATATCCTCCTTAGTTCCTAATCC 
- 
401-7967 CACATGATGGTATGCCTGCGA - controlling the correct 
insertion of the cat 
cassette 401-7968 CCAAGTCTGGATAAGAAAGGC - 
 
a The target gene sequences are shown in bold. The restriction enzyme (R.E.) recognition sites are underlined. 
b Sequences homologous to regions on the Shigella flexneri virulence plasmid (accession number: AF348706) are shown in bold.  
 
PCR products were cloned into the pET28b (+) vector (Novagen) for His-tagged protein production. E.
coli BL21 cells harboring the recombinant plasmids were induced with 0.1 mM IPTG for 3 hours and the 
recombinant proteins were purified from the soluble fraction over IMAC columns (Ni-Sepharose™ 6 Fast 
Flow, GE Healthcare). The antigens were formulated with the adjuvant IC31® that combines the 
immunostimulatory properties of the anti-microbial peptide KLK (20 nmol/mouse), and the 
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oligodeoxynocleotide, ODN1a (0.8 nmol/mouse) [22]. Alternatively, IpaD was used without any adjuvant 
or formulated with the detoxified active subunit of E. coli heat labile toxin (LTA-R192G; 2.5 ȝg/mouse) 
[23]. As control, IC31® was formulated with the B. burgdorferi protein OspA.  
2.2. Animal experiments 
6-8 week-old female BALB/c mice were immunized intranasally 3-times fortnightly with 30 μg 
recombinant protein using the described formulations. Sonicated homologous total cell lysate (30 μg) 
served as positive control. 2 weeks following the last booster mice were challenged with a plasmid-
stabilized derivative of prototype Shigella flexneri 2a strain 2457T. In this mutant the invasion plasmid 
was labeled with a cat cassette at an inert site between virG and the downstream IS629 element with the 
Red recombinase method [24] using primers shown in Table 1. Bacteria used for the challenge were 
grown to mid-log phase (OD600: ~ 0.5) in LB supplemented with 10 ȝg/ml chloramphenicol to ensure that 
the inoculum contained plasmid-bearing virulent bacteria. Mice were infected intranasally with 50 ȝl of 
washed bacterial suspension containing approx. 5x106 CFU. 
2.3. ELISA 
Serum IgG and IgA levels were measured in the pre-immune (taken 3 days prior the first 
immunization) and the hyperimmune (taken 1 week following the 2nd and 3rd immunizations) serum 
samples. ELISA plates (Maxisorp, Dako A/S, Denmark) were coated with 50 ng/well of the recombinant 
IpaD protein and blocked with 2% BSA. Serum samples were diluted 1:5000 for IgG and 1:100 for IgA 
determinations. Secondary antibodies were peroxidase-conjugated goat anti-mouse IgG or IgA (Southern 
Biotech, Birmingham, AL), respectively, at 1:1000 dilutions. Data are expressed as ELISA units (OD405nm 
value × serum dilution). 
3. Results 
All mice immunized intranasally with recombinant IpaD alone or IC31® combined with an irrelevant 
antigen (OspA) succumbed to infection within 2-weeks post-infection. In contrast, IpaD adjuvanted with 
IC31® provided significant protection (p < 0.001; LogRank test) in comparison to both the antigen and the 
adjuvant controls (Fig. 1).  Sonicated lysate of strain 2457T used as positive control was fully protective. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Figure 1. Protection by mucosal immunization with IpaD and IC31® in the mouse lung model of shigellosis. 8-week-old female 
BALB/c mice were immunized with the indicated vaccine formulations intranasally 3 times at two-week intervals. Subsequently, 
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mice were infected intranasally with lethal doses of Shigella flexneri 2a. Lethality was monitored for 14 days, statistical evaluation 
was performed by the LogRank (Kaplan-Maier) test. Survival curves are derived from combined data of two independent 
experiments with 20 mice/groups in total. 
 
Furthermore, protective efficacy of IpaD formulated with IC31® versus genetically detoxified LTA 
(LTA-R192G) subunits was also compared. While adjuvantation with IC31® elicited antigen-specific 
protection, LTA-R192G was highly protective by itself in this model (data not shown). This corroborates 
former observations that enterotoxins induce non-specific protection when used as mucosal adjuvants 
[25].  
 
In order to monitor humoral immune responses, serum samples were analyzed by ELISA. We found 
that IpaD-specific serum IgG and IgA levels induced in the presence of IC31® were comparable to those 
obtained by adjuvantation with detoxified LTA and were significantly higher than those triggered by the 
antigen alone (Fig. 2). Lysate-immunized mice developed low levels of IpaD-specific antibodies even 
after three immunizations, suggesting that this protein is present in low amount in the lysate or weakly 
immunogenic in the presence of other Shigella antigens.   
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 2. IpaD-specific serum IgG and IgA levels. Sera of mice immunized with 30 ȝg of IpaD formulated with different adjuvants 
were analyzed by ELISA using 50 ng/well of recombinant IpaD as coating antigen.  Serum samples taken 3 days prior the first 
immunization as well as 1 week following the second and third immunizations were diluted 1:5000 for IgG and 1:100 for IgA 
determinations. Data are expressed as ELISA units (OD405nm value × serum dilution). 
4.  Discussion 
To our knowledge this is the first study showing protective vaccine induced effects by a single protein 
antigen of Shigella. Since IpaD is highly conserved among different Shigella species, it likely elicits 
serotype-independent protection. Noteworthy is that the route of administration as well as adjuvantation 
of IpaD need to be carefully selected in order to achieve an antigen specific protection. Subcutaneous 
immunization using IpaD adjuvanted with Freund’s adjuvant could not elicit significant protection in the 
same model (data not shown). The mucosal adjuvantation with IC31® is also a key element of this 
experimental vaccine. IC31® is a TLR9 dependent fully synthetic and biodegradable adjuvant with very 
good safety profile in humans [26]. The lack of non-specific protection upon intranasal application seen 
in our model suggests that IC31® does not induce local inflammation and potential side-effects, associated 
with other widely used mucosal adjuvants. Since nasal immunization is known to stimulate immunity at 
distant mucosal sites [27-29], it is tempting to assume that mucosal application of protein antigens may 
induce specific protective responses against human shigellosis as well. Recombinant forms of IpaD and 
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potentially other Shigella proteins adjuvanted with IC31® could contribute to the development of an 
affordable and broadly protective vaccine to prevent shigellosis in endemic regions. 
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